Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts (Q39398599)

From Wikidata

Jump to navigation Jump to search

scientific article published on 30 November 2011

Language	Label	Description	Also known as
English	Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts	scientific article published on 30 November 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Jennie Malmberg

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Anna Perols

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Zohreh Varasteh

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Mohamed Altai

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Alexis Braun

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Mattias Sandström

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Ulrike Garske

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Vladimir Tolmachev

8

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Anna Orlova

9

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Amelie Eriksson Karlström

10

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

30 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

European Journal of Nuclear Medicine and Molecular Imaging

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

39

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

481-492

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Her-2-neu expression and progression toward androgen independence in human prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

Untangling the ErbB signalling network

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

Mechanisms of the development of androgen independence in prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

Imaging of HER-2 overexpression in tumors for guiding therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

Radionuclide molecular imaging using Affibody molecules

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

Tumor imaging using a picomolar affinity HER2 binding affibody molecule

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

(99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

The synthesis and chelation chemistry of DOTA-peptide conjugates

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

Chemical synthesis of triple-labelled three-helix bundle binding proteins for specific fluorescent detection of unlabelled protein.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

Targeted therapy in breast cancer: the HER-2/neu gene and protein

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

[(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

Mechanisms underlying the development of androgen-independent prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [⁹⁹(m)Tc(CO)₃](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

68Ga- and 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-1992-9

21 January 2018

Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules

1 reference

https://pubmed.ncbi.nlm.nih.gov/22322933

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Imaging agents for in vivo molecular profiling of disseminated prostate cancer: Cellular processing of [(111)In]-labeled CHX-A″DTPA-trastuzumab and anti-HER2 ABY-025 Affibody in prostate cancer cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/22322933

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22322933

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibod

1 reference

https://pubmed.ncbi.nlm.nih.gov/22322933

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties

1 reference

https://pubmed.ncbi.nlm.nih.gov/22322933

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A gallium-labeled DOTA-alpha-melanocyte- stimulating hormone analog for PET imaging of melanoma metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/22322933

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor

1 reference

https://pubmed.ncbi.nlm.nih.gov/22322933

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00259-011-1992-9

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39398599&oldid=2202841497"